Updates on Acquisition
Update on acquisition of 203,135 Series A Preferred Stock of Krystal Biotech Inc., USA completion of transaction We refer to our disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, vide our letter dated August 8, 2017 regarding agreement to acquire 203,135 Series A Preferred Stock (equivalent to 15.91% fully diluted equity stake on conversion) of Krystal Biotech Inc., United States of America.... Sun Pharma Reports Q1FY18 Results
Dear Sirs, Sub: Press Release Please find enclosed herewith our Press Release relating to first quarter FY18 financials, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Outcome of Board Meeting
The Board of Directors of the Company at their meeting held today duly approved and took on record the limited reviewed Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the first quarter ended June 30, 2017 which are enclosed herewith along with the Limited Review Report of the Auditors on Standalone and Consolidated Financial Results.... Outcome of Committee Meeting
This is to inform you that the Committee of Directors (Allotment) at its meeting held today i.e. on Friday, August 11, 2017 allotted 799 (Seven Hundred and Ninety Nine) equity shares of the Company of Re 1/- each, on exercise of stock options under the Sun Employee Stock Option Scheme - 2015. Accordingly, post the above allotment the paid-up equity share capital of the Company is Rs. 2,39,93,06,980/- (Rupees Two Hundred and Thirty Nine... Sun Pharma's stock dips before quarter's result
Sun Pharmaceutical Industries hit a four-year low of Rs 451 a share on the BSE exchange, a day before the largest medicine exporter is to announce its quarterly results. The stock had fallen five per cent on Wednesday to Rs 474.7, after a 31 per cent drop in sales for US subsidiary Taro. The company had cited a "difficult generic pricing environment" for the downfall.This has mean a nearly 20 per cent drop in the share over 16 trading sessions since the recent high of Rs 588 on July 19. A Bloomberg poll average of 18 analysts says the company is expected to report a 42 per cent decline in net profit for the quarter ending June, due to shrinking margin from the US business. Sun Pharma is also facing a challenge in its earnings. Its unit at Halol in Gujarat continues to be under the US sector regulator, the FDA's watch, hitting sales and profit in the biggest international market. The facility, catering to the US market, first got a warning letter from the FDA in 2015. Even after... Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Valia & Raksha Valia Shares of Hindalco, Sun Pharma soar in volume
In the Nifty50 pack, 18 stocks were trading in green, while 33 stocks were in red. Acquisition
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 This is to inform you that one of the wholly owned subsidiaries of the Company has agreed to acquire by way of allotment to it, 203,135 Series A Preferred Stock (equivalent to 15.91% fully diluted equity stake on conversion) of Krystal Biotech Inc., United States of America, a biopharmaceutical company using gene therapy to develop... Sun Pharma Advanced Research Company Q1 loss widens to Rs 79 cr
Total income of the company, however, rose to Rs 24.62 crore Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Valia & Raksha Valia